A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1192 participants.

Also called NCT07842185

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 1,192 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07842185
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07842185. Randomized; double masking; primary purpose treatment. Start 2026-12-19 (anticipated); primary completion 2030-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acronym
INSTANT-2
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tirofiban Injection
Intervention (Drug)
Tirofiban Injection
Lead sponsor
Xinqiao Hospital of Chongqing (class: other)
Collaborator
The Affiliated Ganzhou Hospital of Nanchang University (class: other)

Record details

Record id
cardio:ct-nct07842185
Content hash
c593732ccf767351335983ffb001f23b7a9d730362cea9d7a357539196833d1d